

Long-term survival and factors associated with mortality in patients with Community-Acquired Pneumonia and COVID-19: A retrospective cohort study

Eduardo Tuta-Quintero¹, Camila Martínez-Ayala², Alirio Bastidas-Goyes^{3,*}, Diana Díaz Quijano⁴, Ivan Guerrero⁵, Sergio Román⁶, Nicolas Peña⁷, Luisa Martínez⁸, María Celedón⁹, Maddy Perdomo-Parra¹⁰

Abstract

Introduction: Community-acquired pneumonia (CAP) is a leading cause of infectious deaths globally (1). In the United States, the estimated incidence of CAP ranges from 106 cases to 164 cases per 10,000 inhabitants. The main objective of this study was to evaluate the survival rates and factors associated with mortality in patients diagnosed with Community-Acquired Pneumonia (CAP) and Coronavirus Disease 2019 (COVID-19) following their hospitalization in Colombia.

Materials and methods: A retrospective cohort study was conducted to assess 12-month survival in patients with CAP and COVID-19 using the Kaplan-Meier method. Stratifications were performed according to age, sex, comorbidities, and disease severity. Additionally, a multivariate analysis using Cox regression was conducted to investigate the risk factors that may have influenced 12-month survival.

Results: A total of 4697 patients were included, with 52.5% having CAP (2464/4697), 32.5% having COVID-19 (1528/4697), and 15% having neither CAP nor COVID-19 (705/4697). The 12-month survival rate was 46.2% for patients with CAP, 74.9% for patients with COVID-19, and 64.4% for patients with neither condition. Cox regression analysis revealed that being male (HR:1.142;95%CI:1.042-1.252;p=0.004), age > 65 years (HR:2.622;95%CI:2.324-2.959;p<0.001), Charlson Comorbidity Index ≥ 3 (HR:1.770;95%CI:1.604-1.954;p<0.001), CURB-65 ≥ 2 (HR:2.081;95%CI:1.874-2.313;p<0.001), and a history of CAP (HR:1.569; 95%CI:1.420-1.735;p<0.001) were associated with increased mortality at 12 months.

Discussion: Survival among patients with CAP at 12 months of follow-up was lower, with identified factors associated with increased mortality, including being male, over 65 years of age, comorbidities, and disease severity as measured by CURB-65.

Keywords: Pneumonia; COVID-19; Survival; Risk Factors; Observational study.

Supervivencia a Largo Plazo y Factores Asociados con la Mortalidad en Pacientes con Neumonía Adquirida en la Comunidad y COVID-19: Un Estudio de Cohorte Retrospectivo

Resumen

Introducción: La neumonía adquirida en la comunidad (NAC) se ha convertido en la principal causa de muerte infecciosa a nivel mundial¹. En Estados Unidos, la incidencia estimada de NAC oscila entre 106 y 164 casos por 10.000 habitantes. El objetivo principal de este estudio es evaluar las tasas de supervivencia y los factores asociados con la mortalidad en pacientes diagnosticados con Neumonía Adquirida en la Comunidad (NAC) y Enfermedad por Coronavirus 2019 (COVID-19) tras su hospitalización en Colombia.

Materiales y métodos: Se llevó a cabo un estudio de cohorte retrospectivo para evaluar la supervivencia a 12 meses en pacientes con NAC y COVID-19, utilizando el método de Kaplan-Meier. Se realizaron estratificaciones por edad, sexo, comorbilidades y gravedad de la enfermedad. Además, se realizó un análisis multivariado utilizando regresión de Cox para investigar los factores de riesgo que pueden haber influido en la supervivencia a 12 meses.

Resultados: Se incluyó a un total de 4697 pacientes, de los cuales el 52,5% tenía NAC (2464/4697), el 32,5% tenía COVID-19 (1528/4697) y el 15% no presentaba ni NAC ni COVID-19 (705/4697). La tasa de supervivencia a 12 meses fue del 46,2% para los pacientes con NAC, del 74,9% para los pacientes con COVID-19 y del 64,4% para los pacientes sin ninguna de las condiciones. El análisis de regresión de Cox reveló que ser hombre (HR: 1,142; IC del 95%: 1,042-1,252; p=0,004), tener más de 65 años (HR: 2,622; IC del 95%: 2,324-2,959; p<0,001), un Índice de Comorbilidad de Charlson ≥ 3 (HR: 1,770; IC del 95%: 1,604-1,954; p<0,001), CURB-65 ≥ 2 (HR: 2,081; IC del 95%: 1,874-2,313; p<0,001) y tener antecedentes de NAC (HR: 1,569; IC del 95%: 1,420-1,735; p<0,001) se asociaron con una mayor mortalidad a los 12 meses.

Discusión: La supervivencia entre los pacientes con NAC a los 12 meses de seguimiento fue más baja, con factores identificados asociados a una mayor mortalidad, incluyendo ser hombre, tener más de 65 años, presentar comorbilidades y la gravedad de la enfermedad medida por CURB-65.

Palabras clave: Neumonía; COVID-19; Supervivencia; Factores de Riesgo; Estudio observacional.

1 Residente de Medicina Interna, Universidad de La Sabana. Chía, Colombia.
<https://orcid.org/0000-0002-7243-2238>

2 School of Medicine, Universidad de La Sabana. Chía, Colombia.
<https://orcid.org/0000-0001-8275-4399>

3 School of Medicine, Universidad de La Sabana. Chía, Colombia.
<https://orcid.org/0000-0002-8873-9779>

4 School of Medicine, Universidad de La Sabana. Chía, Colombia.
<https://orcid.org/0000-0001-8804-0274>

5 School of Medicine, Universidad de La Sabana. Chía, Colombia.
<https://orcid.org/0000-0003-1547-2628>

6 School of Medicine, Universidad de La Sabana. Chía, Colombia.
<https://orcid.org/0000-0002-9564-7063>

7 School of Medicine, Universidad de La Sabana. Chía, Colombia.
<https://orcid.org/0009-0007-9365-1898>

8 School of Medicine, Universidad de La Sabana. Chía, Colombia.
<https://orcid.org/0000-0003-2736-3285>

9 School of Medicine, Universidad de La Sabana. Chía, Colombia.
<https://orcid.org/0000-0003-2914-3809>

10 School of Medicine, Universidad de La Sabana. Chía, Colombia.
<https://orcid.org/0000-0001-8331-0108>

* Autor para correspondencia:
Correo electrónico: alirio.bastidas@unisabana.edu.co

Recibido: 01/10/2024; Aceptado: 15/12/2024

Cómo citar este artículo: E. Tuta-Quintero, *et al.* Long-term Survival and Factors Associated with Mortality in Patients with Community-Acquired Pneumonia and COVID-19: A Retrospective Cohort Study. *Infectio* 2025; 29(2): 61-67
<https://doi.org/10.22354/24223794.1221>

Introduction

Community-acquired pneumonia (CAP) has become the leading cause of infectious deaths worldwide¹. In the United States, the estimated incidence of CAP ranges from 106 to 164 cases per 10,000 inhabitants. In Latin America, this figure can reach 294 cases per 10,000 inhabitants¹⁻³. Despite advances in vaccination, CAP accounts for 5–12% of lower respiratory tract infections requiring hospitalization²⁻⁵. The mortality associated with CAP varies from 5% to 25% in hospital settings and can reach up to 50% in intensive care units (ICUs)²⁻⁴. Among hospitalized patients requiring ICU care, CAP mortality at 3 months post-discharge can increase to 28%, particularly in older adults, those with comorbidities, multi-organ impairment, and low blood oxygen levels⁶⁻⁸.

The coronavirus disease (COVID-19) pandemic has adversely affected the global healthcare system. Approximately 20% of individuals infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) require hospitalization. Of these, up to 81% may need intensive care, with mortality rates varying widely from 40% to 85%⁹⁻¹¹. A study by Cangemi et al.¹³ reported that the overall mortality risk in COVID-19 patients is five times higher than that in patients with CAP. These differences in mortality rates may be related to disease severity, comorbidities, and patient age, highlighting the need to stratify and analyze patient groups with CAP and COVID-19 pneumonia⁹⁻¹³.

To date, medical literature has provided limited information on long-term survival when comparing CAP with SARS-CoV-2 infection, an essential aspect for a comprehensive understanding of both diseases in the context of acute respiratory infections^{13,14}. The objective of our research was to compare the survival of patients with CAP and SARS-CoV-2 pneumonia to that of a control group and to describe the risk factors associated with mortality in these groups.

Materials and methods

A retrospective cohort study on respiratory conditions was conducted on patients diagnosed with CAP, COVID-19, and a control group admitted to the emergency and intensive care services from January 2006 to December 2021. The primary objective of this study was to describe the differences in the survival and clinical characteristics associated with mortality in this population.

Selection Criteria

Inclusion criteria for the study were: age > 18 years, hospitalization for a diagnosis of CAP and COVID-19, and a complete medical history including paraclinical tests, chest radiography, and chest computed tomography (CT) at the time of admission. Patients admitted to palliative care and those who developed nosocomial infections.

CAP is defined as an acute illness associated with at least one of the following signs or symptoms: fever, new cough with

or without sputum production, pleuritic chest pain, dyspnea, or altered breath sounds on auscultation^{2,8}. This was in addition to a chest radiograph showing alveolar or interstitial infiltrates, consolidation, or cavitations with or without pleural effusion appearing within the first 48 h after hospitalization^{2,8}. COVID-19 diagnosis was defined by a positive polymerase chain reaction (PCR) test¹⁵. Patients hospitalized with respiratory symptoms who did not meet the criteria for CAP or COVID-19 were classified as non-CAP/COVID-19. This selection process was carried out by trained healthcare professionals, including doctors and specialized nursing staff, who assessed the patients at the time of their admission to the study center.

Variables

Described variables included age, sex, comorbidities, and previous or current tobacco use, complete blood count, oxygen partial pressure, carbon dioxide partial pressure, bicarbonate, corrected bicarbonate, base excess, arterial oxygen saturation, lactate dehydrogenase, fractional inspired oxygen, oxygen partial pressure/fractional inspired oxygen, creatinine, blood urea nitrogen, chest X-ray, and chest CT; these data were obtained from the medical record at the time of hospital admission. Additionally, the need for ICU care, invasive mechanical ventilation (IMV), and/or vasopressor support was considered. The dependent variable was mortality assessed 12 months after the diagnosis of CAP, COVID-19, or in the control group.

Follow-up and survival information was obtained through phone calls to patients or their relatives. To minimize possible errors in the classification of the outcomes studied, the research team that recorded the clinical data had medical expertise for diagnosing the study conditions. To reduce data entry bias, the information was reviewed by at least two team members.

Sample Size

The sample size was calculated using the data from the studies by Uranga et al.¹⁶, Moreno-Torres et al.¹⁷, and Vestbo et al.¹⁸ reported 12-month survival rates of 88%, 89%, and 93% for patients with CAP, COVID-19, and other respiratory causes, respectively. With an expected loss rate of 5%, confidence level of 95%, and power of 80%, 240 patients per intervention group were required.

Statistical Analysis

Data were transcribed into Research Electronic Data Capture (REDCap) software^{19,20} and analyzed using SPSS version 25. Quantitative variables were summarized using means and standard deviations (SD) for normal distributions and medians with interquartile ranges for non-normal distributions. Normality was assessed using the Shapiro-Wilk test. Qualitative variables were summarized as frequencies and percentages. To compare quantitative variables, ANOVA and Kruskal-Wallis tests were used based on distribution, and for qualitative variables, the chi-square test was used^{21,22}. Twelve-month survival was evaluated graphically using the Kaplan-Meier

method, and the log-rank test was used to assess statistical differences between diseases. The data were then stratified by age, sex, CURB-65, and Charlson index. Time to event was used as the dependent variable in the Cox regression model, with variables selected for inclusion through bivariate analysis using a significance level of $p < 0.2$ and biological plausibility related to mortality^{21,22}. Hazard ratios (HR) for each variable were determined with a significance level of $p < 0.05$. Missing data imputation analysis was performed for variables with less than 10% loss, applying weighted mean imputation for quantitative variables and logistic regression for qualitative variables. Variables with $> 10\%$ data loss were excluded.

Results

General Characteristics of the Population

A total of 4,697 patients were included, with 52.5% having CAP (2,464/4,697), 32.5% having COVID-19 (1,528/4,697), and 15% having neither CAP nor COVID-19 (705/4,697) (Figure 1). The average age of the overall age was 63.9 years (SD: 19.65), and 59.5% of the patients were male (Table 1). Among patients diagnosed with CAP, 48.8% (1,201/2,464) had a history of systemic hypertension, 28.4% (700/2,464) had Chronic Obstructive Pulmonary Disease (COPD), and 12.1% (297/2,464) had diabetes mellitus. Cough was present in 77.8% (1,916/2,462) of patients with CAP compared to 18.3% (280/1,528) with COVID-19 and 44.3% (312/705) in the non-CAP/COVID-19 group. Headache was present in 24.2% (370/1,528) of the COVID-19 patients compared to 7.9% (194/2,462) of the CAP patients and 11.5% (81/705) of the non-CAP/COVID-19 group.

Laboratory Tests and Medical Treatment

Among the general population, 13% (640/4,697) of the total population required vasopressor support, with 19.8% (303/1,528) in the COVID-19 group, 10.4% (257/2,464) in the CAP group,

and 7.1% (50/705) in the non-CAP/COVID-19 group (Table 2). 21.5% (1,011/4,697) of the general population required ICU admission, with 35.6% (544/1,528) in the COVID-19 group, 15.1% (372/2,464) in the CAP group, and 13.5% (95/705) in the control group. Details of the laboratory tests and arterial gases are provided in the supplementary files (supplementary file).

One-Year Survival Analysis

The overall survival rate was 58.3% (Supplementary file). Survival among CAP patients was 46.2%, among COVID-19 patients was 74.9%, and among those with neither CAP nor COVID-19 was 64.4% (Figure 2). The survival rates for men and women were 46.2% and 47.2% for CAP ($p < 0.001$), 73.3% and 78.3% for COVID-19 ($p < 0.001$), and 64.9% and 63.9% for non-CAP/COVID-19 ($p < 0.001$), respectively.

When stratified by age, patients aged > 65 years had a survival rate of 28.2% for CAP ($p < 0.001$), 61.3% for COVID-19 ($p < 0.001$), and 43% for non-CAP/COVID-19 ($p < 0.001$) (Figure 3). When stratified by a Charlson score ≥ 3 , survival was 17% for CAP ($p < 0.001$), 59.4% for COVID-19 ($p < 0.001$), and 49.7% for non-CAP/COVID-19 ($p < 0.001$) (Figure 4). Finally, when stratified by CURB-65 ≥ 2 , survival rates were 15.4% for CAP ($p < 0.001$), 31.5% for COVID-19 ($p < 0.001$), and 20.2% for non-CAP/COVID-19 ($p < 0.001$) (Figure 5).

Cox Regression: Independently Associated Characteristics with Long-term Mortality

Cox regression analysis showed that being male (HR: 1.142; 95% CI: 1.042-1.252; $p = 0.004$), age over 65 years (HR: 2.622; 95% CI: 2.324-2.959; $p < 0.001$), Charlson ≥ 3 (HR: 1.770; 95% CI: 1.604-1.954; $p < 0.001$), CURB-65 ≥ 2 (HR: 2.081; 95% CI: 1.874-2.313; $p < 0.001$), and a history of CAP (HR: 1.569; 95% CI: 1.420-1.735; $p < 0.001$) were associated with increased mortality at one year (Table 3).




Figure 1. Flowchart analyses. CAP: Community-Acquired Pneumonia; COVID-19: coronavirus disease 2019.

Table 1. General characteristics and comorbidities of the population

	Total population n= 4697	CAP n= 2464	Covid-19 n= 1528	No CAP/COVID-19 n= 705	P value
Age years, m(sd)	63.9 (19.65)	67 (20.72)	60.4 (16.23)	60.7 (20.78)	<0.001
Male sex n(%)	2796 (59.5)	1466 (59.5)	917 (60)	413 (58.6)	0.813
Dyspnea n(%)	3038 (64.7)	1747 (70.9)	935 (61.2)	356 (50.5)	<0.001
Cough n(%)	2508 (53.4)	1916 (77.8)	280 (18.3)	312 (44.3)	<0.001
Diarrhea n(%)	526 (11.2)	159 (6.5)	296 (19.4)	71 (10.1)	<0.001
Fever n(%)	2436 (51.9)	1274 (51.7)	849 (55.6)	313 (44.4)	<0.001
Headache n(%)	645 (13.7)	194 (7.9)	370 (24.2)	81 (11.5)	<0.001
Altered consciousness n(%)	467 (9.9)	367 (14.9)	34 (2.2)	66 (9.4)	<0.001
Rales n(%)	2037 (43.4)	1380 (56)	436 (28.5)	221 (31.3)	<0.001
Wheezing n(%)	643 (13.7)	531 (21.6)	60 (3.9)	52 (7.4)	<0.001
Acute myocardial infarction n(%)	204 (4.3)	129 (5.2)	52 (3.4)	23 (3.3)	0.007
Chronic heart failure n(%)	524 (11.2)	418 (17)	50 (3.3)	56 (7.9)	<0.001
Dementia n(%)	353 (7.5)	267 (10.8)	33 (2.2)	53 (7.5)	<0.001
COPD n(%)	912 (19.4)	700 (28.4)	111 (7.3)	101 (14.3)	<0.001
Diabetes n(%)	645 (13.7)	297 (12.1)	272 (17.8)	76 (10.8)	<0.001
Hypertension n(%)	2066 (44)	1201 (48.8)	599 (39.2)	266 (37.7)	<0.001
Asthma n(%)	101 (2.2)	50 (2)	35 (2.3)	16 (2.3)	0.836
Active smoker n(%)	38 (1.9)	6 (3.2)	25 (1.6)	7 (2.3)	0.286
Ex-smoker n(%)	138 (6.8)	13 (6.9)	110 (7.2)	15 (4.9)	0.334
Charlson Comorbidity Index, m(sd)	1.9 (2.15)	1.7 (2.18)	2.3 (2.03)	1.8 (2.18)	<0.001

Notes: m: average; sd: standard deviation; CAP: Community-Acquired Pneumonia; COVID-19: coronavirus disease 2019; COPD: Chronic obstructive pulmonary disease.

Table 2. Corticosteroids, vasopressor support and mechanical ventilation

	Total population n= 4697	CAP n= 2464	Covid-19 n= 1528	No CAP/ COVID-19 n= 705	P value
Dexamethasone n(%)	1330 (65.7)	117 (62.2)	1041 (68.2)	172 (55.8)	<0.001
Septic shock n(%)	640 (13.6)	318 (12.9)	264 (17.3)	58 (8.2)	<0.001
Vasopressor support n(%)	610 (13)	257 (10.4)	303 (19.8)	50 (7.1)	<0.001
ICU n(%)	1011 (21.5)	372 (15.1)	544 (35.6)	95 (13.5)	<0.001
Days in ICU, m(sd)	9.4 (13.99)	10.3 (19.25)	8.9 (7.43)	9.6 (18.92)	0.200
IMV n(%)	638 (13.6)	266 (10.8)	320 (21)	52 (7.4)	<0.001
NIMV n(%)	384 (8.2)	158 (6.4)	165 (10.8)	61 (8.7)	<0.001

Notes: CAP: Community-Acquired Pneumonia; COVID-19: coronavirus disease 2019; n: number; m: average; sd: Standard deviation; ICU: intensive care unit; IMV: invasive mechanical ventilation; NIMV: Non-invasive mechanical ventilation.

Discussion

In this study, we evaluated the 12-month survival of patients admitted with CAP, COVID-19, and a control group. Clinical factors associated with reduced survival rates were also identified. Lower survival at one year was observed in patients with CAP, particularly in men, those older than 65 years, those with a Charlson score ≥ 3 , CURB-65 ≥ 2 , and a history of CAP. The need for vasopressor support and intensive care unit (ICU) admission was higher in patients with COVID-19. The most common symptoms were cough and headache in patients with CAP and COVID-19, respectively. Hypertension, COPD, and diabetes mellitus were more common in patients with CAP. Our analysis shows relevant differences in 12-month survival and clinical characteristics at admission between the two patient populations hospitalized for CAP or COVID-19^{23,24}.

The control group, consisting of patients hospitalized for respiratory symptoms but who did not meet the diagnostic criteria for CAP or COVID-19, provides a valuable baseline for comparison. Unlike the CAP and COVID-19 groups, the non-CAP/COVID-19 patients exhibited a distinct clinical profile, with moderate rates of symptoms, such as cough and headache, bridging the gap between the more severe presentations in the CAP and COVID-19 groups. Stratified analyses further revealed that age > 65 years, high Charlson scores, and CURB-65 severity correlated with decreased survival in this group, paralleling trends seen in CAP and COVID-19 populations. The inclusion of this control group highlights the spectrum of respiratory hospitalizations and emphasizes the heterogeneity of clinical outcomes, enriching the study's overall analysis.

In a population with a history of COPD, Sheikh et al.¹⁴ described a sevenfold higher risk of in-hospital mortality in patients with SARS-CoV-2 pneumonia than in a control group with CAP. Additionally, a median hospital stay of 15.5 days (IQR = 6.8–30.0) was recorded for patients with COVID-19 compared to 5 days (IQR = 3.0–9.0) for the group without SARS-CoV-2 infection¹⁴. In contrast, our results revealed lower survival rates and longer hospital stay in patients with CAP. This could be attributed to greater disease severity and frequency of respiratory failure, as well as impaired lung function and dysfunctional immunity caused by conditions such as COPD, diabetes mellitus, and smoking^{25–27}.

Pathophysiological mechanisms involving chronic inflammation with higher systemic cytokine levels have been described in CAP than in COVID-19. These processes explain greater endothelial damage and platelet activation, which are associated with worse short- and long-term clinical outcomes^{28,29}. However, our study was designed to evaluate the clinical differences and long-term survival between COVID-19 and CAP, and not to identify differences related to endothelial biomarker analysis and their association with clinical outcomes^{28,29}.

A prospective observational study by Cangemi et al.¹³ reported a higher incidence of thromboembolic events and in-hospital mortality associated with thrombosis in patients with COVID-19 than in those with CAP. Although our results assessed long-term mortality, we observed lower survival rates in patients with CAP¹³. It is crucial to highlight that thromboembolic events in patients with SARS-CoV-2 infection significantly contribute to short-term mortality, underscoring the need to evaluate the long-term outcomes in patients with COVID-19 and CAP. However, both studies observed similarities in patients with CAP upon hospital admission. These patients were older, predominantly male, and had a higher burden of cardiovascular and pulmonary disease¹³.

In our study, patients with COVID-19 had higher long-term survival rates and a lower burden of associated comorbidities. At the time of hospital admission, the COVID-19 population was younger, predominantly male, and had a shorter ICU stay. Our findings highlight differences in comorbidity burden between patients with CAP and COVID-19, which may explain the lower 12-month survival rate in patients with CAP due to a higher incidence of hypertension, chronic obstructive pulmonary disease, and diabetes mellitus (23,24). It is important to note that a significant percentage of COVID-19 patients may remain asymptomatic or experience mild to moderate respiratory symptoms. However, in our study, a considerable number of patients with SARS-CoV-2 infection presented symptoms such as diarrhea and headache, which increased the risk of developing long-term COVID^{10–12}. Nevertheless, more studies are needed to evaluate the relationship between comorbidity burden and the risk of developing “long COVID” with long-term fatal clinical outcomes.




Figure 2. General survival by disease. CAP: Community-Acquired Pneumonia; COVID-19: coronavirus disease 2019.




Figure 3. Age adjusted survival. CAP: Community-Acquired Pneumonia; COVID-19: coronavirus disease 2019.




Figure 4. Charlson index adjusted survival. CAP: Community-Acquired Pneumonia; COVID-19: coronavirus disease 2019.




Figure 5. CURB-65 score adjusted survival. CAP: Community-Acquired Pneumonia; COVID-19: coronavirus disease 2019.

Table 3. Cox Regression: Independently Associated Characteristics with Mortality

Variable	HR	CI 95%	p-value
Male sex	1.142	1.042-1.252	<0.001
Charlson Comorbidity Index >3	1.770	1.604-1.954	0.004
CURB-65 >2	2.810	1.874-2.313	<0.001
Age >65 years	2.622	2.324-2.959	<0.001
History of CAP	1.569	1.420-1.735	<0.001
LR chi2(5) = 1158.63			
p-value: <0.001			

Notes: HR: Hazard Ratio; CAP: Community-Acquired Pneumonia.

The elderly population is at a higher risk of developing respiratory infections due to multiple comorbidities, alterations in the immune system, decreased cellular regeneration capacity, and reduced respiratory reserve^{30,31}. Our study supports these data by identifying a significant association between reduced one-year survival, age over 65 years, and Charlson score ≥ 3 . Additionally, factors such as reduced vaccine efficacy in older adults and those with comorbidities may also be linked to increased susceptibility to severe diseases and worse clinical outcomes^{30,31}.

Limitations

The limitations of our study include its observational nature and the omission of information obtained from clinical records. It is worth noting that the staff responsible for data collection was trained in data transcription. Our study included sufficient subjects to test the proposed hypothesis. However, the cause of death at 12 months could not be determined, which might have provided important information. Future studies that corroborate our findings are warranted. Additionally, evaluating and comparing the effect of thrombosis and embolism events on 12-month mortality in patients with CAP and COVID-19 has been investigated¹³.

In conclusion, this study described lower survival in patients with CAP at 12 months of follow-up, identifying factors associated with reduced survival, such as being male, age > 65 years with comorbidities, and severe pneumonia. Patients with COVID-19 presented with a higher need for support and intensive care along with symptoms and comorbidities.

Ethical considerations

This study involved human participants and was conducted according to the Declaration of Helsinki and was approved by the institutional ethics committee of the Universidad de La Sabana (Acta No. 20220102).

Protection of persons. Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Protection of vulnerable populations. Not applicable

Confidentiality. During the collection and analysis of the data, the protocols established by the participating institutions were followed, ensuring the privacy of the patients. Protection of vulnerable populations.

Privacy. Not applicable

Financing. Universidad de La Sabana (code: Grant MEDM-SC-28-2024).

Conflict of interests. The authors have no conflict of interest to declare.

Acknowledgments. The study was carried out at the Universidad de La Sabana.

Authors' contribution. Conceptualization, data curation and formal analysis were performed by ETQ, CMA, ABG, and DDQ. Investigation, software analysis and laboratory assays were performed by ETQ, CMA, ABG, and DDQ. Writing, editing, and review were performed by IG, SR, NP, LM, MC, and MPP. All authors contributed to read and approved the version of the submitted manuscript.

References

- Eshwara VK, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: An update. *Indian J Med Res.* 2020 ;151(4):287-302. DOI: 10.4103/ijmr.IJMR_1678_19
- Gadsby NJ, Musher DM. The Microbial Etiology of Community-Acquired Pneumonia in Adults: from Classical Bacteriology to Host Transcriptional Signatures. *Clin Microbiol Rev.* 2022 ;35(4):e0001522. DOI: 10.1128/cmr.00015-22
- Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. *Intensive Care Med.* 2023 ;49(6):615-632. DOI: 10.1007/s00134-023-07033-8
- Pletz MW, Blasi F, Chalmers JD, Dela Cruz CS, Feldman C, Luna CM, et al. International Perspective on the New 2019 American Thoracic Society/ Infectious Diseases Society of America Community-Acquired Pneumonia Guideline: A Critical Appraisal by a Global Expert Panel. *Chest.* 2020 ;158(5):1912-1918. DOI: 10.1016/j.chest.2020.07.089
- Nair GB, Niederman MS. Updates on community acquired pneumonia management in the ICU. *Pharmacol Ther.* 2021 ;217:107663. DOI: 10.1016/j.pharmthera.2020.107663
- Arnold FW, Wiemken TL, Peyrani P, Ramirez JA, Brock GN; CAPO authors. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. *Respir Med.* 2013 ;107(7):1101-11. DOI: 10.1016/j.rmed.2013.04.003
- Carlos P, Gomes R, Coelho J, Chaves C, Tuna C, Louro M. CURB-65 and Long-Term Mortality of Community-Acquired Pneumonia: A Retrospective Study on Hospitalized Patients. *Cureus.* 2023 ;15(3):e36052. DOI: 10.7759/cureus.36052
- Surme S, Balkan II, Bayramlar OF, Kara Ali R, Mete B, et al. Predictors of Long-term Outcomes in the Older Adults with Community-Acquired Pneumonia. *J Infect Dev Ctries.* 2021 ;15(12):1910-1916. DOI: 10.7759/cureus.36052
- Long B, Carius BM, Chavez S, Liang SY, Brady WJ, Koyfman A, et al. Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. *Am J Emerg Med.* 2022 ;54:46-57. DOI: 10.1016/j.ajem.2022.01.028
- Alharthy A, Aletreby W, Faqih F, Balhamar A, Alaklobi F, Alanezi K, et al. Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study. *J Epidemiol Glob Health.* 2021 ;11(1):98-104. DOI: 10.2991/jegh.k.200928.001
- Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et

- al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*. 2020 ;323(16):1574-1581. DOI: 10.1001/jama.2020.5394
12. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020 ;323(11):1061-1069. DOI: 10.1001/jama.2020.1585
 13. Cangemi R, Calvieri C, Falcone M, Cipollone F, Ceccarelli G, Pignatelli P, et al. Comparison of Thrombotic Events and Mortality in Patients with Community-Acquired Pneumonia and COVID-19: A Multicenter Observational Study. *Thromb Haemost*. 2022 ;122(2):257-266. DOI: 10.1055/a-1692-9939
 14. Sheikh D, Tripathi N, Chandler TR, Furmanek S, Bordon J, Ramirez JA, et al. Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non- SARS-CoV-2 community-acquired pneumonia. *Respir Med*. 2022 ;191:106714. DOI: 10.1016/j.rmed.2021.106714.
 15. Alsharif W, Qurashi A. Effectiveness of COVID-19 diagnosis and management tools: A review. *Radiography (Lond)*. 2021 ;27(2):682-687. DOI: 10.1016/j.radi.2020.09.010.
 16. Uranga A, Quintana JM, Aguirre U, Artaraz A, Diez R, Pascual S, Ballaz A, España PP. Predicting 1-year mortality after hospitalization for community-acquired pneumonia. *PLoS One*. 2018 Feb 14;13(2):e0192750. DOI: 10.1371/journal.pone.0192750
 17. Moreno-Torres V, Muñoz-Serrano A, Calderón-Parra J, Mills-Sánchez P, Pintos-Pascual I, Rodríguez-Olleros C, et al. Mortality by COVID-19 Before Vaccination - One Year Experience of Hospitalized Patients in Madrid. *Int J Infect Dis*. 2022 ;116:339-343. doi: 10.1016/j.ijid.2022.01.043.
 18. Vestbo J, Waterer G, Leather D, Crim C, Diar Bakerly N, Frith L, et al. Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD. *Eur Respir J*. 2022 ;59(5):2102899. DOI: 10.1183/13993003.02899-2021
 19. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009 ;42(2):377-81. DOI: 10.1016/j.jbi.2008.08.010
 20. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*. 2019 ;95:103208. DOI: 10.1016/j.jbi.2019.103208
 21. Hosmer DW, Lemeshow S, Sturdivant RX. Special Topics. In: Hosmer DW, Lemeshow S, Sturdivant RX, editors. *Applied Logistic Regression*, 3rd ed. New York, NY: John Wiley & Sons, Inc; 2013. p. 401-408.
 22. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. *Journal of clinical epidemiology* 1996; 49: 1373-1379. DOI: 10.1016/s0895-4356(96)00236-3
 23. Tuta-Quintero E, Torres-Arevalo D, Bastidas-Goyes AR, Aponte-Murcia HC, Guerrero M, Giraldo A, et al. Survival at 3, 6 and 12 months in patients diagnosed with community-acquired pneumonia in Colombia: a retrospective cohort study. *Braz J Infect Dis*. 2024 Jul- ;28(4):103852. DOI: 10.1016/j.bjid.2024.103852
 24. Tuta-Quintero E, Bastidas AR, Guerrón-Gómez G, Perna-Reyes I, Torres D, García L, et al. Performance of risk scores in predicting mortality at 3, 6, and 12 months in patients diagnosed with community-acquired pneumonia. *BMC Pulm Med*. 2024 ;24(1):334. DOI: 10.1186/s12890-024-03121-7
 25. Błach J, Siedliński M, Sydor W. Immunology in COPD and the use of combustible cigarettes and heated tobacco products. *Eur J Med Res*. 2023 ;28(1):397. DOI: 10.1186/s40001-023-01374-2
 26. de Lourdes Ochoa-González F, González-Curiel IE, Cervantes-Villagrana AR, Fernández-Ruiz JC, Castañeda-Delgado JE. Innate Immunity Alterations in Type 2 Diabetes Mellitus: Understanding Infection Susceptibility. *Curr Mol Med*. 2021;21(4):318-331. DOI: 10.2174/1566524020999200831124534
 27. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. *Eur Respir J*. 2008 ;31(6):1334-56. DOI: 10.1183/09031936.00018908
 28. González-Jiménez P, Méndez R, Latorre A, Mengot N, Piqueras M, Reyes S, et al. Endothelial Damage, Neutrophil Extracellular Traps and Platelet Activation in COVID-19 vs. Community-Acquired Pneumonia: A Case-Control Study. *Int J Mol Sci*. 2023 ;24(17):13194. DOI: 10.3390/ijms241713194
 29. Palma Medina LM, Babačić H, Dzidic M, Parke A, Garcia M, Maleki KT, et al. Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia. *Respir Res*. 2023 ;24(1):62. DOI: 10.1186/s12931-023-02364-y
 30. Häder A, Köse-Vogel N, Schulz L, Mlynska L, Hornung F, Hagel S, et al. Respiratory Infections in the Aging Lung: Implications for Diagnosis, Therapy, and Prevention. *Aging Dis*. 2023 ;14(4):1091-1104. DOI: 10.14336/AD.2023.0329
 31. Mogilenko DA, Shchukina I, Artyomov MN. Immune ageing at single-cell resolution. *Nat Rev Immunol*. 2022 ;22(8):484-498. DOI: 10.1038/s41577-021-00646-4